Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Krishnansu Tewari

Showing results (11-20 of 11) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 11 results.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 4, 2023
A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancerRobert W Holloway, Premal Thaker, Alberto A Mendivil, et al.
Pageof 2

Showing results (11-20 of 11) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 11 results.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 4, 2023
A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancerRobert W Holloway, Premal Thaker, Alberto A Mendivil, et al.
Pageof 2